dual neprilysin/natriuretic peptide-C receptor inhibtor (Mayo Clinic/Bayer HealthCare)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual neprilysin/natriuretic peptide-C receptor inhibtor (Mayo Clinic/Bayer HealthCare)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNatriuretic peptides stimulantsNatriuretic peptide receptor 3 antagonistsNeprilysin inhibitors
TargetsNatriuretic peptidesNeprilysinNatriuretic peptide receptor 3
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMayo ClinicBayer HealthCare AG
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A